4DMedical (ASX:4DX) Altman Z2-Score: -6.34 (As of Jun. 27, 2026)


ASX:4DX 4DMedical Ltd ASX:4DX
64 GF Score
Price A$4.16
GF Value A$1.44
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is 4DMedical Altman Z2-Score?

4DMedical ASX:4DX -8.97% 64 Altman Z2-Score is -6.34 as of Jun. 27, 2026. GuruFocus rates ASX:4DX with a GF Score™ of 64/100 and a GF Value™ of A$1.44 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 845 Medical Devices & Instruments companies, 4DMedical ranks worse than 79.64% on this metric.

Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.

Warning Sign:

4DMedical has a Altman Z2-Score of -6.34, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

The zones of discrimination were as such:

When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.

The historical rank and industry rank for 4DMedical's Altman Z2-Score or its related term are showing as below:

ASX:4DX' s Altman Z2-Score Range Over the Past 10 Years
Min: -21.09   Med: -1.07   Max: 11.47
Current: -6.34

During the past 6 years, 4DMedical's highest Altman Z2-Score was 11.47. The lowest was -21.09. And the median was -1.07.


4DMedical  (ASX:4DX) Altman Z2-Score Explanation

The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4_2, Net Worth (Total Stockholders Equity - Preferred Stock)/Total Liabilities (NW/TL): it compares a company’s stock net worth with its total liabilities and can be used to assess the extent of its reliance on debt.

Read more about Altman Z2-Score, the original research on Z-Score and the additional research on Z2-Score.


Be Aware

Altman Z2-Score does not apply to financial companies.


4DMedical Altman Z2-Score Related Terms


4DMedical Altman Z2-Score Historical Data

* Premium members only.

The historical data trend for 4DMedical's Altman Z2-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4DMedical Altman Z2-Score Chart

4DMedical Annual Data
Trend Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Altman Z2-Score
Get a 7-Day Free Trial 11.47 2.75 1.67 -3.80 -6.34

4DMedical Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Altman Z2-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -3.80 0.00 -6.34 0.00

ASX:4DX vs ABT, SYK, MDT: Altman Z2-Score Comparison

For the Medical Devices subindustry, 4DMedical's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


4DMedical Altman Z2-Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, 4DMedical's Altman Z2-Score distribution charts can be found below:

* The bar in red indicates where 4DMedical's Altman Z2-Score falls into.


ASX:4DX
64GF Score
4DMedical Ltd ASX:4DX
Altman Z2-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

4DMedical Altman Z2-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.

4DMedical's Altman Z2-Score for today is calculated with this formula:

Z=6.56*X1+3.26*X2+6.72*X3+1.05*X4_2
=6.56*-0.0231+3.26*-1.9207+6.72*-0.318+1.05*2.1008
=-6.34

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.

Trailing Twelve Months (TTM) ended in Jun. 2025:
Total Assets was A$94.81 Mil.
Total Current Assets was A$17.06 Mil.
Total Current Liabilities was A$19.26 Mil.
Retained Earnings was A$-182.11 Mil.
Pre-Tax Income was A$-30.16 Mil.
Interest Expense was A$-0.01 Mil.
Total Liabilities was A$30.58 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(17.062 - 19.255)/94.812
=-0.0231

X2=Retained Earnings/Total Assets
=-182.107/94.812
=-1.9207

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(-30.157 - -0.009)/94.812
=-0.318

X4_2=Net Worth/Total Liabilities
=(Total Stockholders Equity - Preferred Stock)/Total Liabilities
=(64.235 - 0)/30.576
=2.1008

The zones of discrimination were as such:

Distress Zones - 1.1 < Grey Zones < 2.6 - Safe Zones

4DMedical has a Altman Z2-Score of -6.34 indicating it is in Distress Zones.

Frequently Asked Questions Learn more about Altman Z2-Score →
What does a Altman Z2-Score of -6.34 mean?
4DMedical (ASX:4DX) has a Altman Z2-Score of -6.34 as of Jun. 27, 2026. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on 4DMedical and its competitors. According to the industry distribution chart, 4DMedical ranks #673 out of 845 companies in the Medical Devices & Instruments industry, placing it in the top 79.6%.
Is 4DMedical's Altman Z2-Score too high?
4DMedical's current Altman Z2-Score is -6.34. Based on the distribution chart, 4DMedical ranks #673 out of 845 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, 4DMedical has a GF Score™ of 64/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does 4DMedical's Altman Z2-Score compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, 4DMedical ranks #673 out of 845 companies for Altman Z2-Score. This places 4DMedical in the lower half of its industry. The industry median Altman Z2-Score is 3.48. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z2-Score for a Medical Devices & Instruments company?
The median Altman Z2-Score among Medical Devices & Instruments companies is 3.48, based on 845 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z2-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z2-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z2-Score mean?
A high Altman Z2-Score can signal that a stock is expensive relative to its fundamentals. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on 4DMedical and its competitors. For the Medical Devices & Instruments industry, the median Altman Z2-Score is 3.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. 4DMedical's current Altman Z2-Score is -6.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 4DMedical stock overvalued right now?
Based on GuruFocus' analysis, 4DMedical (ASX:4DX) is currently considered Significantly Overvalued. The stock's GF Value™ is A$1.44, compared to a current price of A$4.16 — trading 188.9% above its estimated fair value. The current Altman Z2-Score is -6.34. 4DMedical's overall GF Score™ is 64/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z2-Score calculated?
Altman Z2-Score is calculated from a company's financial statements. For 4DMedical (ASX:4DX), the current Altman Z2-Score is -6.34 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is 4DMedical (ASX:4DX) Overvalued in 2026?

Based on GuruFocus' analysis, 4DMedical stock appears to be overvalued. The current stock price of A$4.16 is trading 188.9% above its estimated GF Value™ of A$1.44. GuruFocus considers 4DMedical to be Significantly Overvalued.

Key valuation signals for ASX:4DX:

  • Altman Z2-Score: -6.34
  • GF Value™: A$1.44 vs. price of A$4.16 (188.9% above fair value)
  • GF Score™: 64/100 with 2 warning signs

No single metric tells the full story. See the ASX:4DX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


4DMedical Business Description

Other Exchanges FDMDF:USAMQ7:Germany
Address 700 Swanston Street, Level 7, Melbourne Connect, Carlton, VIC, AUS, 3053
4DMedical Ltd is a company focused on medical research technology and the development of a non-invasive respiratory imaging solution using four-dimensional imaging. The four-dimensional lung imaging technology utilizes mathematical models and algorithms to convert X-ray scans into quantitative data, aiding physicians in managing patients with respiratory and lung diseases.
64GF Score

Get the complete analysis for ASX:4DX

Altman Z2-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$4.16
Price
A$1.44
GF Value